Sinusitis - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 93
Price : Single User: US $ 2000  US $ 1600 Corporate User: US $ 6000  US $ 4500
Inquire Before Buying
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's, ‘Sinusitis - Pipeline Review, H2 2016', provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sinusitis

  • The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects

  • The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Sinusitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Sinusitis

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Sinusitis - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sinusitis Overview 7
Therapeutics Development 8
Pipeline Products for Sinusitis - Overview 8
Sinusitis - Therapeutics under Development by Companies 9
Sinusitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Sinusitis - Products under Development by Companies 14
Sinusitis - Companies Involved in Therapeutics Development 15
AmpliPhi Biosciences Corporation 15
F. Hoffmann-La Roche Ltd. 16
Knopp Biosciences LLC 17
Kyorin Pharmaceutical Co., Ltd. 18
Kyowa Hakko Kirin Co., Ltd. 19
Merck & Co., Inc. 20
Oticpharma Ltd 21
Paratek Pharmaceuticals, Inc. 22
Pfizer Inc. 23
Quorum Innovations LLC 24
Regeneron Pharmaceuticals Inc 25
Therabron Therapeutics, Inc. 26
Sinusitis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ABSA-01 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
benralizumab - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CG-201 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
dexpramipexole dihydrochloride - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
dupilumab - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
fluticasone propionate - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
KRPAM-1977X - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
omadacycline tosylate - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
omalizumab - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
P-008 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
PCL-1404 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
PF-06817024 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Qi-117 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
RG-6149 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecule for Sinusitis - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules for Chronic Rhinosinusitis - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
solithromycin - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Sinusitis - Dormant Projects 86
Sinusitis - Product Development Milestones 87
Featured News & Press Releases 87
Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress 87
Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus 87
Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort 88
Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab 88
Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association 89
Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01 89
Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections 90
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 90
Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables

Number of Products under Development for Sinusitis, H2 2016 8
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Sinusitis - Pipeline by AmpliPhi Biosciences Corporation, H2 2016 15
Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16
Sinusitis - Pipeline by Knopp Biosciences LLC, H2 2016 17
Sinusitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 18
Sinusitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 19
Sinusitis - Pipeline by Merck & Co., Inc., H2 2016 20
Sinusitis - Pipeline by Oticpharma Ltd, H2 2016 21
Sinusitis - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 22
Sinusitis - Pipeline by Pfizer Inc., H2 2016 23
Sinusitis - Pipeline by Quorum Innovations LLC, H2 2016 24
Sinusitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 25
Sinusitis - Pipeline by Therabron Therapeutics, Inc., H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Sinusitis - Dormant Projects, H2 2016 86

List of Figures

Number of Products under Development for Sinusitis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Top 10 Targets, H2 2016 28
Number of Products by Stage and Top 10 Targets, H2 2016 28
Number of Products by Top 10 Mechanism of Actions, H2 2016 30
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30
Number of Products by Routes of Administration, H2 2016 32
Number of Products by Stage and Routes of Administration, H2 2016 32
Number of Products by Molecule Types, H2 2016 34
Number of Products by Stage and Molecule Types, H2 2016 34
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global ENT Disorder Treatment Market 2017-2021
    Published: 10-May-2017        Price: US 3500 Onwards        Pages: 70
    ENT also known as otolaryngology, is an area of medicine that deals with disorders of ear, nose, and throat. Dysfunction of these body parts can affect quality of life and in certain cases may even lead to medical emergency. The market encompasses drugs that are used for the treatment of the ENT disorder. It mainly considers the various drug class used for the treatment of numerous symptoms of the disease. The major ENT disorders included in the report are rhinitis, sinusitis, otitis media, a......
  • Sinusitis - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 95
    Sinusitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis - Pipeline Review, H1 2017, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape. Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruct......
  • Tinnitus - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 59
    Tinnitus - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Pipeline Review, H1 2017, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape. Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in t......
  • Global Hearing Disorders Partnering 2010 to 2017
    Published: 01-Apr-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the hearing disorders partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Hearing Disorders Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • To......
  • Meniere Disease - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 44
    Meniere Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Pipeline Review, H1 2017, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape. Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in ......
  • Nasal Polyposis - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 48
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyposis - Pipeline Review, H1 2017, provides an overview of the Nasal Polyposis (Ear Nose Throat Disorders) pipeline landscape.Nasal polyps (NP) are non cancerous growths within the nose or sinuses. Symptoms include runny nose, snoring, itchiness, persistent stuffy, facial pain, loss of taste. Risk factors include asthma, cystic fibrosis, Churg-Strauss syndrome and allergic fungal sinusitis. Treatment ......
  • Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017
    Published: 28-Feb-2017        Price: US 2000 Onwards        Pages: 35
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore t......
  • Otitis Media - Pipeline Review, H1 2017
    Published: 28-Feb-2017        Price: US 2000 Onwards        Pages: 82
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H1 2017, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasona......
  • Tonsillitis-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs